GET DAILY SIGNALSBionano Genomics (BNGO) Drops -26% Over 30 Days on Earnings Miss and Cash Concerns
Key Takeaways
- Bionano Genomics (BNGO) shares fell roughly 26% over the last 30 days, sliding from about $1.37 to near $1.02, as a sharp mid-September rally fully unwound.
- A third-quarter earnings miss in early November, with revenue and per-share loss both coming in below consensus, accelerated the decline in the final stretch of the period.
- Thin cash reserves of about $8.7 million, a going-concern disclosure, and a warrant-related registration filing reinforced investor concerns about potential dilution.
- Over the last quarter, the stock is down roughly 14%, reflecting a volatile spike followed by a steady drift lower rather than a single uninterrupted decline.
- Positive reimbursement catalysts, including a proposed MolDX local coverage determination and new peer-reviewed studies, supported the stock earlier but failed to hold the gains.
- For additional details on this ticker, investors can explore Bionano's Price Targets, Earnings, and Forecast pages.
- To monitor automated trading signals across the market, readers can review the Trending AI Robots section.
Company Background and Market Position
Bionano Genomics, headquartered in San Diego, California, develops genome analysis solutions built around optical genome mapping (OGM), a technology used to detect structural variants in DNA. Its product portfolio includes the Saphyr and Stratys systems, nanochannel-array flow cell consumables, the VIA software platform for genomic data analysis, and Ionic systems for nucleic acid purification. Through its Bionano Laboratories subsidiary, the company also offers CLIA-certified laboratory-developed tests.
OGM is positioned as a complement to traditional cytogenetics methods such as karyotyping and fluorescent in situ hybridization, with particular traction in hematologic malignancies, genetic disorders, and reproductive genomics. As of its third-quarter 2026 report, Bionano cited an installed base of 398 OGM systems. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors follow the stock closely because its growth depends on clinical adoption, reimbursement coverage, and the company's ability to manage a constrained cash position while scaling toward profitability.
Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, BNGO declined approximately 26%, moving from a closing price near $1.37 to roughly $1.02. The drop was concentrated in the final sessions of the period, after the company reported third-quarter results that missed consensus estimates.
The broader quarterly picture is more volatile. About three months ago, the stock traded near $1.18. In mid-September it spiked dramatically, reaching an intraday high above $2.20 on unusually heavy volume before closing near $1.56, only to give back those gains over the following weeks. From that mid-August baseline of about $1.18 to the recent level near $1.02, the stock is down roughly 14% for the quarter, underscoring that much of the 30-day decline represents an unwinding of a short-lived rally.
Key Drivers Behind the Recent 30-Day Decline
The primary catalyst over the last 30 days was Bionano's third-quarter 2026 earnings report. Revenue of $8.28 million rose 12.3% year over year but fell short of consensus estimates, and the reported net loss per share was wider than analysts expected. Software revenue declined 31% year over year, while gross margin moderated from the record level set in the prior quarter. Management reiterated full-year 2026 revenue guidance of $31 million to $33 million, but the top-line miss and cautious tone weighed on sentiment.
Balance-sheet concerns compounded the pressure. The company reported cash, investments, and restricted cash of roughly $8.7 million and reiterated going-concern language that references the need for significant additional financing. A registration statement filed in late October related to the potential exercise of outstanding warrants, which could generate substantial gross proceeds but also create dilution, added to investor unease. Supply constraints on critical silicon wafer components also continued to limit flow cell capacity through year-end.
Performance Drivers Across the Full Quarter
The quarter was defined by a burst of positive clinical and reimbursement news followed by renewed focus on financial durability. In early-to-mid September, Bionano announced a proposed MolDX local coverage determination for OGM in hematologic neoplasms spanning 31 states, New York State Department of Health approval of OGM-based lab-developed tests, and three new peer-reviewed studies demonstrating the clinical value of OGM in high-risk myeloid cancers. These developments helped fuel the sharp mid-September price spike.
However, that momentum faded as attention returned to the company's cash runway, the need for additional capital, and the transition of some software customers toward OGM, which pressures near-term software revenue. The November earnings miss then crystallized those concerns, leaving the stock lower over the full three-month period despite the earlier rally.
Looking Ahead: Key Factors for Investors to Monitor
Several factors are likely to shape Bionano's trajectory in the coming months. The final determination on the proposed MolDX local coverage determination remains a key catalyst, as Medicare coverage clarity could support broader clinical adoption of OGM. Investors will also monitor progress toward the company's 2027 framework of $50 million to $54 million in revenue and adjusted EBITDA neutrality by the end of 2027, a target that requires a significant acceleration in growth.
Financing and liquidity will remain central to the narrative, given the thin cash position and the need for additional capital. The resolution of silicon wafer supply constraints and the planned doubling of flow cell capacity in mid-2027 will also influence whether the company can meet demand. Finally, continued reimbursement developments, new clinical publications, and adoption by large reference customers will be important indicators of whether the company can convert clinical momentum into sustainable revenue growth. From what I see, I’m watching this closely as these elements unfold.
Exploring AI Tools for Market Insights
In my view, using systematic tools can help put individual stock movements like this one into broader context. I often turn to Tickeron’s AI Trading Bots to review automated strategies that have performed across similar volatile names, which provides a helpful layer of data without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
BNGO sees MACD Histogram crosses below signal line
BNGO saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 38 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNGO as a result. In 74 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
BNGO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNGO crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for BNGO entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BNGO's RSI Oscillator exited the oversold zone, 37 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in 165 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
BNGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.429) is normal, around the industry mean (4.964). P/E Ratio (-0.382) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technologies for analysis of large biological molecules
Industry PharmaceuticalsOther
Advertisement